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Abstract
Background: Human cell lines are the most innovative choice of host cell for production of
biopharmaceuticals since they allow for authentic posttranslational modification of therapeutic
proteins. We present a new method for generating high and stable protein expressing cell lines
based on human amniocytes without the requirement of antibiotic selection.
Results: Primary amniocytes from routine amniocentesis samples can be efficiently transformed
with adenoviral functions resulting in stable human cell lines. Cotransfection of the primary human
amniocytes with a plasmid expressing adenoviral E1 functions plus a second plasmid containing a
gene of interest resulted in permanent cell lines expressing up to 30 pg/cell/day of a fully
glycosylated and sialylated protein. Expression of the gene of interest is very stable for more than
90 passages and, importantly, was achieved in the absence of any antibiotic selection.
Conclusion: We describe an improved method for developing high protein expressing stable
human cell lines. These cell lines are of non-tumor origin, they are immortalized by a function not
oncogenic in human and they are from an ethically accepted and easily accessible cell source. Since
the cell can be easily adapted to growth in serum-free and chemically defined medium they fulfill
the requirements of biopharmaceutical production processes.
Background
For many therapeutic proteins post-translational modifi-
cations, proteolytic processing and oligomerization of
multiple chains are important for protein functionality,
stability and efficient secretion. Even though some modi-
fications can occur in yeast and bacterial expression sys-
tems, mammalian and preferably human cells are the host
of choice for proteins that require authentic glycosylation
or other post-translational modifications. For production
of biopharmaceuticals, there is a permanent demand for
improved methods for cell line development featuring
shorter time lines, higher productivity, improved consist-
ency and genetic stability.
Rapid production of small quantities of protein can be
achieved by transient transfection of the appropriate
mammalian cell line. In contrast, large-scale protein pro-
duction depends on a stable cell line with the protein
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expressing genetic construct integrated in the host
genome. The development of a permanent production
cell line and the manufacturing process for a recombinant
protein usually follows a well-established scheme. For
screening purposes and for maintenance of protein
expression potent selection markers need to be used and
producer cells have to be constantly cultivated in medium
containing the respective selective agent. The two expres-
sion cassettes – one expressing the protein of interest, the
second containing the selection marker – can either be
located on different plasmids, or can be incorporated in
one plasmid, preferably expressed from the same pro-
moter by taking advantage of an internal ribosomal entry
site (IRES) [1]. By transfection and subsequent constant
selection in the appropriate selection medium producer
cell lines are selected which express high levels of the pro-
tein of interest. Classical selection markers like glutamine
synthetase (GS) [2,3], dihydrofolate reductase (DHFR)
[4,5], hypoxanthine guanine phosphoribosyl transferase
(HPRT) [6,7] or herpes simplex virus TK [8,9] genes can
only be used in cells deficient for the respective gene.
Alternatively, genes that confer resistance to cytotoxic
drugs can be used like kanamycin, neomycin, geneticin
and blasticidin [10].
Usually, the development and selection of an optimized
permanent producer cell line is a very time-consuming
procedure which can last for months and includes selec-
tion for cell clones with highest expression levels, limited
dilution to obtain genetically identical cell clones and
testing for stability of expression during multiple pas-
sages. Expression levels of the protein of interest depend
on numerous factors including the promoter, cellular lev-
els of relevant transcription factors, presence of factors
transactivating the promoter, the number of gene copies
within the cell and the chromatin structure at the integra-
tion site [11].
The site of integration has a major effect on the transcrip-
tion of the gene of interest. Therefore, integrations into
transcriptional active chromatin sites are preferred. How-
ever, very frequently the gene of interest is rapidly inacti-
vated and thus silenced [12,13]. Several strategies to
overcome this position effect have been developed and
include the use of regulatory elements like matrix attach-
ment regions and insulators flanking the gene of interest
[14]. In addition, specific targeting of the gene of interest
into transcriptionally active sites of the genome using
yeast or phage recombinases seems to be a possible
option [15,16].
The production of authentic human proteins is best
addressed by the use of human cell lines, because they are
not expected to add potentially immunogenic glycan
structures to the protein of interest. However, there are
only a few human cell lines described and restricted access
or deficient documentation limit their use in biopharma-
ceutical production. Among the cell lines used are
HEK293 (E1-transformed human embryonal kidney/neu-
ronal cells) [17], HKB11 (HEK293 cells fused with a
Burkitt's lymphoma cell) [18], PerC6 (E1-transformed
human embryonal retina cells) [19], and E1-transformed
human amniocyte cells [20,21].
We describe here a novel method for rapid generation of
human production cell lines capable of secreting high lev-
els of proteins without any need for antibiotic selection.
Our approach was to co-transfect primary human amnio-
cytes with two plasmids, one expressing adenoviral E1-
gene products and a second expressing a therapeutic pro-
tein. Transformed cell clones were obtained which show
high and stable expression of the glycosylated therapeutic
protein. Development of these cell lines did neither
require genetic knock-out of internal marker genes, nor
cotransfection of a selection marker, nor selection of
clones in medium containing antibiotics.
Results
Primary amniocytes can be efficiently transformed by 
adenoviral E1-functions
In order to test if primary amniocytes can be used to estab-
lish permanent, therapeutic protein expressing cell lines,
amniocytes were cotransfected with the E1-expressing
plasmid pGS119 containing E1A-, E1B- and pIX-functions
plus the plasmid pGS116 expressing the human alpha-1
antitrypsin (hAAT) glycoprotein.
The primary amniocytes used here originated from a sin-
gle amniocentesis sample. About 20–30 days after trans-
fection of approximately 1 × 106  cells, numerous
transformed cell colonies appeared on all dishes, and cells
on the dishes were expanded as 10 pools (Z171-1A, B –
Z171-5A, B). Non-transformed cells stop growth already
at early passages and in approximately passage 10–15
mainly transformed cells can be detected on the dishes.
Since transfection efficiency of primary cells is less than
1% (data not shown) the efficiency of transformation is
very high, however, because cells were passaged twice the
number of independently transformed clones could not
be determined. Such high frequencies were obtained
without difference in numerous transfections using differ-
ent cells from several amniocentesis (data not shown).
Expression of the E1 proteins was analyzed by Western
Blot using protein extracts of different cell pools. Like
HEK293 cells used as positive control, all cell pools
express both the E1A- and 21kD-E1B proteins, although
in different amounts and ratios (Fig. 1).BMC Biotechnology 2008, 8:13 http://www.biomedcentral.com/1472-6750/8/13
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Primary amniocytes show variable morphologies. In con-
trast, transformed cells do appear smaller and show more
uniform morphologies. In very early passages the mor-
phologies in different cell pools are quite similar but
change during further cultivation. Most transformed cells
go through mild crisis and decelerate growth but recover
during only few passages.
Transformed amniocytes express and secrete hAAT
As described above, the primary amniocytes were cotrans-
fected with a hAAT-expressing plasmid. hAAT is a major
human serum protein which is predominantly produced
and efficiently secreted from hepatocytes. Thus we tested
for secreted (Fig. 2a) and intracellular (Fig. 2b) hAAT in
different cell pools. Using Western Blot analyses we were
able to detect hAAT expression in 6 out of 10 different cell
pools. The amount of protein loaded per lane for the
intracellular and secreted protein corresponds to 8 × 104
cells and 4 × 103 cells, respectively. These results suggest
that hAAT is very efficiently secreted from the cells since
only small amounts of the protein were intracellularly
located.
Amniocyte cell lines show high and long-lasting hAAT 
expression
The above results show that both plasmids integrated
upon cotransfection and cells express proteins from both
plasmids. The lack of selective pressure during cell passag-
ing most likely does not influence expression of E1-func-
tions since their continuous presence is expected to be
crucial to maintain the transformed phenotype of the
cells. Therefore, we tested for the stability of expression of
hAAT during multiple passages.
Six Z171 cell pools showed expression of hAAT in early
passages and were thus further cultivated up to 35–50 pas-
sages. In different passages 7 × 105 cells were plated, the
supernatants were collected and the amounts of secreted
hAAT were quantitated. In figure 3 the amount of hAAT in
6 different cell pools is depicted and shows that 4 out of 6
Expression of E1 proteins Figure 1
Expression of E1 proteins. Western Blot analyses for E1A and 21-kDa E1B proteins expressed in 10 E1-transformed amni-
ocyte cell pools. Cells were lysed and proteins were size fractionated on a SDS-containing polyacrylamide gel. Proteins were 
transferred to nitrocellulose and probed with anti-E1A or anti-E1B 21-kDa antibody. Protein lysates from HEK293 or primary 
amniocytes were used as control.
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cell pools show high and long-lasting hAAT expression up
to 6 μg/ml. Only in two cell pools the hAAT expression
drops drastically to almost not detectable expression lev-
els after 30 passages. Two cell pools (Z171-5A and Z171-
5B) stably express up to 8 pg hAAT per cell and day for
more than 50 passages without any antibiotic selection.
Since each cell pool is derived from numerous different
transformation and integration events and thus contains
many genetically different cell lines, we performed single
cell cloning on cell pools Z171-5A and Z171-5B by lim-
ited dilution in 96-well plates. Thirteen single cell clones
originating from Z171-5A and 25 single cell clones origi-
nating from Z171-5B were expanded and tested for hAAT
expression (data not shown). Figure 4 shows long term
expression of hAAT of 3 clonal cell lines each originating
from pool Z171-5A and Z171-5B, respectively. Over 60
passages all 6 clonal cell lines express hAAT; in 2 clonal
lines maximum hAAT levels reach 27 and 30 pg/cell/day.
hAAT expressed in amniocyte cell lines is glycosylated and 
sialylated
Human alpha-1 antitrypsin is a 396- amino acid serum
glyoprotein and contains three carbohydrate side chains
N-linked to asparagine residues. Analyses of the carbohy-
drate composition revealed two main A- and B-types oli-
gosaccharide chains (see Fig 5c) in 2:1 ratio [22,23].
Glycosylation of hAAT does not seem to be important for
the formation of a biologically active conformation with
elastase and thus for activity of the protein [24]. However,
glycosylation seems to play a crucial role in stability of
hAAT in the serum [25,26] and in secretion from hepato-
cytes [27].
In order to test if amniocyte cell lines produce glyco-
sylated hAAT we treated the cell culture supernatants of
Z171-5A (Fig. 5) and Z171-5B (data not shown) with
PNGaseF, followed by hAAT-specific Western Blotting.
Since PNGaseF cleaves between the innermost GlcNAc
Expression of hAAT protein Figure 2
Expression of hAAT protein. Western Blot analyses for hAAT protein expressed in 10 E1-transformed amniocyte cell 
pools. (A) For detection of secreted hAAT, proteins in the cell culture medium were fractionated on a SDS-containing polycr-
ylamide gel. (B) For detection of intracellular hAAT, cells were lysed and proteins were separated on a SDS-containing polyacr-
ylamide gel. Intracellular and secreted hAAT was visualized using a monoclonal anti-hAAT antibody. For control proteins from 
untransformed amniocytes and hAAT purified from human plasma were used.
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and asparagine residue of oligosaccharides from N-linked
glycoproteins (see Fig. 5c) we expected a shift in molecu-
lar weight if PNGaseF can hydrolyze N-glycan chains from
hAAT. For control we used hAAT purified from human
serum. Digestion with increasing amounts of PNGaseF
results in a clear shift in molecular weight (Fig 5a). More-
over, appearance of three distinct bands clearly suggests
the presence of three glycan chains in the recombinant
product. There is no difference in size and number of dif-
ferent protein bands when compared to hAAT purified
from human serum.
All galactoside residues in plasma derived hAAT are
known to be linked with sialic acid. To test for this feature
in hAAT expressed in amniocyte cell lines, protein
secreted into the cell culture medium of Z171-5A was
digested with Neuraminidase followed by hAAT-specific
Western Blotting (Fig. 5b). Comparable to plasma derived
hAAT, the hAAT produced in Z171-5A showed a shift in
size when treated with Neuraminidase.
These results indicate that hAAT produced in human
amniocyte cell lines are fully glycosylated and sialylated.
Discussion
Increased and detailed knowledge about the precise car-
bohydrate structures has revealed the importance of post-
translational modifications for functionality of therapeu-
tic proteins. However, these findings also exposed that the
list of modifications is frighteningly long and many of
them might affect the immunogenicity, stability, pharma-
cokinetics and thus efficacy of the protein. The most
important capability that distinguishes mammalian cells
from other expression systems is N- and O-linked glyco-
sylation and it is assumed that around 2% of the human
genome encodes proteins that contribute to glycosylation
Quantitation of hAAT expression in 6 amniocyte cell pools Figure 3
Quantitation of hAAT expression in 6 amniocyte cell pools. Cells in different passages were plated into 6-well plates, 
the supernatants were collected after 72 hours and the amounts of secreted hAAT were analysed by ELISA.
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[28]. Although almost any mammalian cell line possesses
the machinery to produce and secrete proteins, only a lim-
ited number meet the fermentation requirements and
thus can be used for industrial manufacturing: Chinese
hamster ovary (CHO), baby hamster kidney (BHK) and
mouse myeloma cells NS0 and Sp2/0.
Glycan structures differ significantly among different cell
types and species. Only human cells lines promise to pro-
duce proteins in a way that species-specific and thus
immunogenic differences in glycosylation are absent. For
safety and regulatory reasons human cells used for pro-
duction should not be of tumor origin. In addition, only
a limited number of human cell lines are available to date.
The development of permanent cell lines using primary
human cells and recombinant DNA techniques has been
hampered by the fact that human cells are highly resistant
to transformation by viral functions. In fact, from human
tissue sources only human embryonic kidney (HEK) cells
[17], human embryonic lung (HEL) cells [29], human
embryonic retinoblasts (HER cells) [30,19] and primary
human amniocytes [20] have been successfully trans-
formed with adenoviral functions. For practical and ethi-
cal reasons it is very difficult to obtain primary cells from
fetal origin. Primary human amniocytes are the only cell
type that is readily available without ethical concerns:
they can be collected by routine amniocentesis. Human
amniocytes can be cultivated as adherent cultures for sev-
eral passages under standard conditions and consist of
three main cell types, fibroblast-like, epithelial-like and
amniotic fluid (AF) cells [31]. Recently it has been shown,
that about 1% of cells found in amniotic fluid are amni-
Quantitation of hAAT expression in 6 clonal amniocyte cell lines Figure 4
Quantitation of hAAT expression in 6 clonal amniocyte cell lines. Single cell cloning was performed from amniocyte 
cell pools Z171-5A and Z171-5B in passages 26 and 27, respectively. Clonal cells in different passages were plated into 6-well 
plates, the supernatants were collected after 48 hours and the amounts of secreted hAAT were analysed by ELISA.
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Glycoanalyses of hAAT Figure 5
Glycoanalyses of hAAT. Proteins from cell culture medium of amniocyte cell pool Z171-5A were treated with increasing 
amounts of (A) PNGaseF or with (B) Neuraminidase and fractionated on SDS-containing polyacrylamide gels. Upon transfer on 
nitrocellulose Western Blot analyses were performed using a monoclonal anti-hAAT antibody. For controls hAAT purified 
from human plasma was used. (C) A- and B-type oligosaccharide chains of hAAT and cut positions of PNGaseF and Neuramin-
idase.
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otic-fluid derived stem (AFS) cells [32]. Considering the
low transfection efficiency (< 1% in the present analyses)
of human amniocytes, the transformation efficiency using
an E1-expressing plasmid is surprisingly high. In earlier
studies we have calculated to obtain at least one or two
transformants in 1 × 105  cells transfected [20]. Even
though in the present analyses we have transfected two
plasmids, one containing the E1 and pIX genes and a sec-
ond expressing hAAT with a plasmid ratio of 1:1, the
transformation efficiency was comparable to transfection
with the E1-plasmid alone (data not shown).
Cotransfection of two plasmids expressing the transform-
ing E1-functions and hAAT, respectively, resulted in stably
transformed cell pools, with 6 out of 10 pools expressing
hAAT. Moreover, 4 out of 6 cell pools show long-lasting
expression for more than 35 passages, with expression lev-
els up to 6 μg/ml or 8 pg/cell/day. Cell cloning by limited
dilution from two cell pools resulted in genetically identi-
cal cell lines which show stable expression of hAAT for
more than 65 passages (the time course of the present
study) with expression levels up to 30 pg/cell/day. Since
cloning of cells was started in passage 26, this indicates
stable expression of hAAT for more than 90 passages.
Again it has to be emphasized that this stable protein
expression was achieved without any antibiotic selection.
The majority of the mammalian genome is transcription-
ally silent. Since integration of transfected plasmids
occurs randomly, the position effects generally manifest
partial or complete loss of expression. In order to over-
come the position effect numerous regulatory elements
introduced into the plasmid expressing the gene of inter-
est have been tested including insulators, MARs, strong
promoters and enhancers. Even when using such ele-
ments a time consuming testing of numerous cell clones
over multiple passages cannot be avoided. Other crucial
parameters like the choice of promoters for expressing the
gene of interest and the marker gene, the ratio of gene of
interest to marker gene expressing plasmid, concentration
of selection marker in the medium or using linear versus
circular plasmids considerably influence cell line develop-
ment and expression levels.
In common strategies to select for highly expressing cell
lines, the marker gene is linked to the gene of interest and
employing a selection strategy can circumvent the prob-
lem of silencing. However, even under selective pressure
only a very minor number of cell clones yield in high and
stable expression of the gene of interest. In addition, the
selective pressure has to be maintained throughout cell
line development. Currently, aminoglycoside antibiotics
such as hygyromycin B and Geneticin are frequently used.
These substances interfere with protein translation and
exhibit highly toxic effects in mammalian cells not con-
taining the corresponding bacterial genes. However, these
antibiotics are also described to have undesired side
effects like increasing frequency of sister chromatid
exchange [33] and altering expression of glucose-regu-
lated genes [34].
A different very popular strategy for high-level protein
production is based on the use of dhfr-deficient CHO cells
in combination with expression vectors carrying a func-
tional dhfr gene and the gene of interest. Cultivation of
these transfected cells in methotrexate (MTX) containing
medium results in amplification of the dhfr gene and gene
of interest sequences and thus high-level expression of the
gene of interest. The disadvantage of this production sys-
tem however is, that cells grown in the presence of MTX
often show substantial heterogenicity in chromosomal
location and copy number of amplified sequences, they
exhibit rearrangement and highly variable amplification
of transfected sequences, and they contain chromosomes
with highly extended regions, chromosomes joined at
amplified regions or even circular chromosomes consist-
ing entirely of exogenous DNA. Thus the use of the dhfr-
amplification system very often results in a high degree of
genetic instability in the production cell line [35].
As described earlier, the permanent expression of E1-func-
tions is crucial for maintaining the transformed character
of stable cell lines [36]. Thus, the E1-functions are replac-
ing the selection marker and prevent the repressive effect
of the surrounding heterochromatin. Earlier analyses have
shown, that transfection of two plasmids into CHO cells
results in co-integration at a common site in all clones
examined [37]. Since in the present analyses 4 out of 6 cell
pools show long-lasting expression of hAAT, we assume
that the hAAT-expressing plasmid has co-integrated in a
transcriptionally active site. Single cell cloning of the cell
pools resulted in stable cell lines exhibiting very high pro-
tein expression of up to 30 pg/cell/day. The E1-functions
have been shown to increase expression from several pro-
moters including the CMV promoter [38-40] used in the
present analyses, which might contribute to the high
expression levels.
Primary human amniocytes are efficiently transformed by
adenoviral E1-functions. Based on this observation, we
exhibit an improved method for developing high protein
expressing stable human cell lines. These cell lines can be
easily adapted to serum-free suspension culture by gradu-
ally exchanging the medium to a serum-free, chemically
defined medium for suspension cells (data not shown).
Moreover, hAAT expressed as reference protein in human
amniocyte cell lines is fully glycosylated and sialylated. In
future experiments we plan to perform a more detailed
analyses of the glycan structure of hAAT expressed inBMC Biotechnology 2008, 8:13 http://www.biomedcentral.com/1472-6750/8/13
Page 9 of 11
(page number not for citation purposes)
human amniocyte cell lines in comparison to the protein
expressed in CHO cells.
Industrial protein expression demand short time lines for
cell line development, use of chemically derived serum
free medium, growth in suspension and the possibility to
scale up production process. Only during the very early
passages the primary amniocytes depend on fetal serum
but are soon transferred to chemically derived serum-free
medium. For technical reasons transformation and isola-
tion of permanent cell clones occurs in adherent culture,
and thus an additional step for adaptation to growth in
suspension has to be admitted. We have started additional
experiments in order to simplify and speed up this adap-
tation step and thus shorten the time frame for cell line
development.
The potential of the present novel method of cell line
development however is not restricted to production of
biopharmaceuticals. For example, cotransfection of pri-
mary amniocytes with the E1-expressing plasmid and a
second plasmid expressing SV40 T-antigen or Epstein-Barr
virus EBNA-1 protein would result in cell lines that would
be optimized for transient protein expression. Moreover,
overexpression of glycosylation enzymes like the α2–6
sialyltransferase would result in cells optimized for pro-
duction of glycosylated proteins with high sialic acid con-
tent. Additional examples would be the expression of
certain viral proteins in cells lines for improved produc-
tion of viruses for vaccination or gene therapy. The current
method would also allow the insertion of certain DNA-
sequences like FLP recombinase targets (FRT) sites by sim-
ply introducing FRT sites in the E1-expressing plasmid. By
cotransfecting such new cells with a plasmid expressing
the gene of interest flanked by FRT sites and a FLP express-
ing plasmid, a recombinase mediated cassette exchange
would occur. The insertion of the gene of interest would
then occur at a predicted site and thus would drastically
simplify cell line development.
Conclusion
We have shown that cotransfection of primary amniocytes
with two plasmids, one expressing transforming adenovi-
ral E1-functions and the second plasmid expressing hAAT
as a gene of interest, resulted in high hAAT-expressing cell
lines. In this new human cell lines protein expression of
up to 30 pg/cell/day was stable for more than 90 passages
and was accomplished without antibiotic selection. More-
over, the hAAT produced in the new amniocyte cell lines
was fully glycosylated and sialylated. This new method
shows an efficient way of developing stable and human
cell lines from a non-tumorgenic, ethically accepted and
easily available cell source.
Methods
Plasmids
Plasmid pGS116 contains the human cytomegalovirus
(hCMV) promoter, followed by a Simian virus 40 (SV40)
intron, the human alpha-1 antitrypsin (hAAT) cDNA and
the SV40 polyadenylation site. Plasmid pGS119 was used
to transform primary human amniocytes and contains the
E1 and pIX region of adenovirus type 5 (Ad5) from nt.
505 to 4079. E1A is under the control of the murine phos-
phoglycerate kinase (pgk) promoter, while E1B and pIX
expression is controlled from their natural promoters. The
E1B downstream intron, splice acceptor and polyA signal
were replaced by corresponding motifs from SV40.
Primary cells and cell lines
Primary amniocytes were derived from routine clinical
amniocentesis usually performed during week 16–20 of
gestation for prenatal diagnosis. Amniocytes were
obtained including patients informed consent as redun-
dant material not required for clinical diagnosis. Thus, the
amniotic fluid was used in accordance with all legal and
ethical requirements. Primary cells were cultivated in
Ham's F10 medium supplemented with L-glutamine (Inv-
itrogen), 10% fetal calf serum (FCS), 2% Ultroser G
(BioSpepra) antibiotic/antimycotic (Invitrogen) in 5%
CO2 at 37°C. After several passages cells were stepwise
adapted to Opti-Pro medium (Invitrogen), supplemented
with Ultroser. HEK-293 cells were cultivated in alpha
modified Eagle's medium (αMEM, Invitrogen) supple-
mented with 10% FCS and antibiotics in 5% CO2 at 37°C.
Transfection and expansion of transformed amniotic cells
Five 6-cm dishes with subconfluent cultures of amnio-
cytes adapted to Opti-Pro medium (see above) were trans-
fected with 1 μg per dish of each pGS116 and pGS119
using Effectene transfection kit (Qiagen). Both plasmids
were digested with ScaI prior to transfection. The next day,
transfected cells were transferred to 15-cm dishes and
Ultroser was reduced to 1%. About 20 to 30 days post
transfection cells from each dish were transferred to two
15-cm dishes; individual cell clones arising from single
transformed cells appear on the transfected dishes several
days later. These clones were expanded as clone pools by
passaging the cells on individual dishes and further culti-
vation for several passages until untransformed amnio-
cytes stopped growing and were overgrown by
transformed cells. Genetically identical clones of two
pools of Z171 in passage 26 (for Z171-5A) and 27 (for
Z171-5B) were isolated by limited dilution in 96-well
plates and further expanded. Passage numbering of
cloned cells started again with passage one in 96-well
plates.BMC Biotechnology 2008, 8:13 http://www.biomedcentral.com/1472-6750/8/13
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Expression of E1 proteins
For detection of E1 protein expression Western Blots were
performed using monoclonal antibodies. 7 × 105 cells/
well from Z171 cell pools were plated on 6-well plates and
harvested 72 h later by detaching the cells in Tris-Saline/4
mM EDTA, pelleting and lysing cells in loading buffer
containing SDS. For control either untransfected primary
amniocytes or untransfected HEK293 cells were used. The
proteins were separated in a 10% SDS-polyacrylamid gel,
transferred to nitrocellulose and incubated with either an
anti-E1A or an anti-E1B-21kD antibody (Oncogene
Research), and anti-mouse (E1A, Jackson ImmunoRe-
search Laboratories) or anti-rat (E1B-21kD, Oncogene
Research) as secondary antibody and visualized by chem-
oluminescence.
Expression of hAAT (Western Blot)
The intracellular and secreted hAAT expression in differ-
ent cell lines were analysed in a Western Blot using a mon-
oclonal antibody. 7 × 105 cells/well from each Z171 cell
pool were plated on 6-well plates. Seventy-two hours later
the supernatants were collected, cells were counted and
lysed as described above. For detection of intracellular
expression of hAAT proteins, cell lysates were separated
on a 10% SDS-Gel. For detection of secreted hAAT, 10 μl
of the cell culture media were applied on a 10% SDS-gel.
Intracellular and secreted hAAT was visualized by chemo-
luminescence using a monoclonal anti-hAAT antibody
(ICN Biomedicals), and an anti-goat antibody (Pierce). As
negative controls, proteins from untransfected primary
amniocytes were used. As positive control, hAAT purified
from human plasma (ICN Biomedicals) was used.
Quantitation of hAAT expression (ELISA)
The amount of hAAT secreted into the cell culture
medium was quantitated using the enzyme-linked immu-
noabsorbent assay (ELISA). From different passages of
each Z171 cell pool 7 × 105 cells/well were plated on 6-
wells plates. Forty-eight or 72 hours later the supernatants
of the different cell lines were collected. The amount of
hAAT secreted into the medium was quantitated by ELISA
using polyclonal hAAT-antibodies (HRP-coupled and
uncoupled, ICN Biomedicals). As standard, different
amounts of hAAT purified from human plasma were used.
The hAAT levels were either calculated in μg expressed per
ml medium or as pg/cell expressed in 24 h per cell using
the numbers of cells initially plated.
Glycoanalyses of hAAT
The glycosylation of hAAT expressed in Z171-5A and
Z171-5B was analysed by cleaving N-linked oligosaccha-
rides from hAAT using the peptide-N-glycosidase F
(PNGaseF). To 22.5 μl cell culture medium, 2.5 μl of
denaturing buffer (5% SDS, 10% β-Mercaptoethanol) was
added. After denaturing for 10 min at 96°C, 3.5 μl G7-
reaction buffer (New England Biolabs, 10× containing
500 mM Na-phosphate buffer), 3.5 μl 10% NP-40 and
different amounts of PNGaseF (500, 50, 5 and 0 U/μl,
New England Biolabs) were added and incubated for 1 h
at 37°C. For control either hAAT purified from human
plasma or 22.5 μl of cell culture medium were denatured
and incubated either with PNGaseF or H2O as described
above.
For detection of sialic acid linked to galactose residues,
hAAT secreted into the cell culture medium was incubated
with Neuraminidase. This enzyme catalyzes the hydroly-
sis of α2–3, α2–6 and α2–8 linked N-acetyl-neuraminic
acid residues from glycoproteins. To 22.5 μl cell culture or
medium plasma derived hAAT, 2.5 μl G1-reaction buffer
(New England Biolabs, 10× containing 500 mM sodium
citrate) and 3 μl Neuraminidase (50 U/μl, New England
Biolabs) or 3 μl H2O was added and incubated for 1 h at
37°C.
Controls and digested proteins were separated in an SDS-
polyacrylamide gel and Western Blotting using anti-hAAT
antibodies was performed as described above.
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